As well as supporting users with classical drug-discovery NMR processes, such as screening of ligand libraries, we offer support in structure-based drug design.
We develop methods to enable application of structure-based drug design by NMR to non-labelled, large proteins. Members of HWB-NMR are developers of INPHARMA (Interligand NOEs for PHArmacophore Mapping), which allows the binding mode of low-affinity ligands to macromolecular receptors to be determined using small amounts of non-labelled target protein of any molecular size. References